NasdaqGS:AMGNBiotechs
Amgen And Zai Lab DLL3 Alliance Adds New Dimension To Oncology Story
Amgen (NasdaqGS:AMGN) and Zai Lab have agreed to a global clinical trial collaboration focused on small cell lung cancer.
The partnership will evaluate a combination of two DLL3 targeting therapies, Amgen's IMDELLTRA and Zai Lab’s zocilurtatug pelitecan.
This is described as a first of its kind combination of a BiTE therapy and an antibody drug conjugate in this setting.
Amgen, trading at $349.82, has seen its share price move 2.1% over the past week and 6.8% year to date, with a 22.8%...